60 F
New York
Friday, May 7, 2021

Humanigen [NASDAQ: HGEN] Announces Expansion Of Manufacturing Agreement With Ajinomoto Bio-Pharma

Must read

Coinbase Pro Announces it will be Listing Internet Computer’s ICP

Coinbase Pro cryptocurrency exchange has disclosed that it has decided to list ICP once it goes live. ICP is the governance token of the...

WISeKey [NASDAQ: WKEY] Gets Investment to finance its TrustNFT.IO NFT Platform

WISeKey International Holding AG disclosed Friday that it has inked a term-sheet to enter into an unsecured short-term loan and the issuance and...

Moderna [NASDAQ: MRNA] Inks Supply Agreement with Switzerland

Moderna, Inc. disclosed that it has inked a supply agreement on Thursday with the Swiss Federal Government. As per the agreement, Moderna Inc...

TeraBlock Will Have its Own BSCPad IDO Soon

TeraBlock which is a project making a platform for automated cryptocurrency portfolio management disclosed that it is preparing for an initial DEX offering (IDO)...

Humanigen Inc [NASDAQ: HGEN] revealed that the company has extended the manufacturing agreement with  Ajinomoto BioPharma to support the fill-finish of Lenzilumab. The Lenzilumab is the phase 3 treatment option for Covid19 which is currently in development.

Ajinomoto will provide drug product aseptic fill-finish service to Humanigen at its San Diego facility. By doing so the company will simplify the supply chain efforts for Humanigen to support continuing clinical trials efforts. Meanwhile, Humangien is keenly registering patients in the United States and Brazil for a phase 3 study. Moreover, the company is preparing applications for Covid 19 EUA for Lenzilumab.

Cameron Durrant CEO of Humanigen said “ We are glad to join forces with Ajinomoto BioPharma to support the fil finish of Lenzilumab. Moreover, The collaboration will enable us to use Ajinomoto’s drug product aseptic fill-finish facility to provide the timely supply of Lenzilumab.  We are nearly at end of the clinical study of phase 3 and ready for Emergency Use Authorization applications.”

More articles

Latest article

Why Chiasma [NASDAQ: CHMA] Stock is Skyrocketed?

Shares of Chiasma, Inc. surged 46.48% during the trading session of Wednesday. Chiasma has disclosed the financial results for the Q1 completed March...

NeoGenomics [NASDAQ: NEO] Announces Acquisition of Inivata Ltd

NeoGenomics, Inc. revealed Wednesday that it has decided to purchase Inivata Ltd. Inivata will grow into a liquid biopsy-centered division together with increasing...

R1 RCM [NASDAQ: RCM] Announces Acquisition of VisitPay

R1 RCM Inc. disclosed Tuesday that it has decided to purchase VisitPay. The firm has inked an agreement to buy VisitPay for nearly...

Binance Coin Makes History as its Market Cap Reach $100 Billion

The market capitalization of Binance set new records as the exchange token of Binance and the native asset of Binance Smart Chain (BSC) touched...

Precipio [NASDAQ: PRPO] Roll Out Rapid COVID-19 Antibody test on Amazon Platform

Shares of Precipio, Inc. skyrocketed 40.35% during the trading session of Monday. The strong performance of the firm has highlighted the positive sentiments...

TechX Ink Deal to Buy Fiat-to-Crypto Merchant Services Gateway XPort Digital

TechX Technologies Inc disclosed Monday that it has bought fiat-to-crypto merchant services gateway XPort digital. The firm has bought a 100% stake in XPort...

Lockheed [NYSE: LMT] Present F-35 Best and Final Offer to Finnish Government

Lockheed Martin Corporation disclosed that it has presented F-35 best and final offer (BAFO) on April 29, 2021, to the Finnish government. It...

Clene [NASDAQ: CLNN] Gets Two Patent Notice of Allowances

Clene Inc. disclosed that Clene Nanomedicine, Inc. U.S. Patent and Trademark Office has provided Notices of Allowance for two significant patent applications. Clene...